Figure 2.

Changes in the HER2-enriched signature upon treatment with CDK4/6 inhibitors +/− fulvestrant in vitro. (A) Heatmap of a multiclass SAM representing the PAM50 molecular subtypes, proliferation score and genes that are differentially expressed (FDR < 5%) in T47D, MCF7, and BT474 cells treated with CDK4/6 inhibitors (100 or 500 nM) +/− fulvestrant (1 nM). Three independent mRNA extractions per cell line were performed. (B) Paired samples t-test analyses showing changes in the HER2-enriched signature following treatment of T47D, MCF7, and BT474 cells with CDK4/6 inhibitors (100 or 500 nM) +/− fulvestrant (1 nM). Three independent mRNA extractions and gene expression analyses were performed for each cell line.